AstraZeneca PLC (FRA:ZEG)

Germany flag Germany · Delayed Price · Currency is EUR
143.65
-1.10 (-0.76%)
Last updated: Oct 21, 2025, 9:00 AM CET
-0.76%
Market Cap223.12B
Revenue (ttm)48.11B
Net Income (ttm)7.06B
Shares Outn/a
EPS (ttm)4.52
PE Ratio31.59
Forward PE17.14
Dividend2.91 (2.02%)
Ex-Dividend DateAug 7, 2025
Volume15,737
Average Volume506
Open143.50
Previous Close144.75
Day's Range143.30 - 144.55
52-Week Range113.25 - 148.50
Betan/a
RSI60.76
Earnings DateNov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]

Industry Pharmaceutical Preparations
Founded 1992
Employees 94,300
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol ZEG
Full Company Profile

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD Financial Statements

News

The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies

Zacks spotlights AstraZeneca, RTX, and Applied Materials for strong performance and growth potential, while microcap names Park Aerospace and NetSol Technologies show niche momentum.

23 hours ago - Nasdaq

Trump’s pharma strategy ‘holds Europe hostage’, Finnish MEP warns

Trump’s deals with Pfizer, AstraZeneca, and Merck expose risk to EU

1 day ago - EURACTIV.com

Top Research Reports for AstraZeneca, RTX & Applied Materials

AstraZeneca, RTX, and Applied Materials stand out in today's Zacks Research Daily with strong performance drivers and key growth catalysts.

1 day ago - Nasdaq

AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure

AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure

1 day ago - GuruFocus

AstraZeneca hails major breakthroughs with breast-cancer drugs

An executive at AstraZeneca says breast-cancer drugs that the company highlighted at an industry conference over the weekend could represent $10 billion worth of company sales in five years’ time.

1 day ago - MarketWatch

AstraZeneca: CHMP Recommends Saphnelo For Approval

(RTTNews) - AstraZeneca (AZN) said its Saphnelo or anifrolumab has been recommended for approval in the European Union as a self-administered once-weekly pre-filled pen for adult patients with systemi...

2 days ago - Nasdaq

AstraZeneca (AZN) Reports Positive Phase III Trial Results for Datroway

AstraZeneca (AZN) Reports Positive Phase III Trial Results for Datroway

2 days ago - GuruFocus

AstraZeneca (AZN) Reports Success in Breast Cancer Trial with Enhertu

AstraZeneca (AZN) Reports Success in Breast Cancer Trial with Enhertu

2 days ago - GuruFocus

AstraZeneca (AZN) Reports Promising Results in Breast Cancer Trial

AstraZeneca (AZN) Reports Promising Results in Breast Cancer Trial

2 days ago - GuruFocus

Significant Trial Results Boost AstraZeneca's ENHERTU in Breast Cancer Treatment

Significant Trial Results Boost AstraZeneca's ENHERTU in Breast Cancer Treatment

2 days ago - GuruFocus

AZN: Promising Results from DESTINY-Breast11 Phase III Study

AZN: Promising Results from DESTINY-Breast11 Phase III Study

2 days ago - GuruFocus

Top global stories this week: AstraZeneca, Taiwan Semiconductor Manufacturing among notable names

US stock indexes ended the week higher, supported by encouraging earnings reports from major U.S. banks.

2 days ago - Seeking Alpha

AstraZeneca's Datroway extends survival in aggressive breast cancer

AstraZeneca and Daiichi Sankyo's new breast cancer drug helped significantly extend survival in some patients in a late-stage trial, marking a potential breakthrough in one of the hardest-to-treat for...

3 days ago - Reuters

AstraZeneca : ENHERTU Shows Significant Survival Benefit In DESTINY-Breast05 Phase III Trial

(RTTNews) - AstraZeneca announced that the Phase III DESTINY-Breast05 trial demonstrated ENHERTU (fam-trastuzumab deruxtecan-nxki) significantly improves invasive disease-free survival (IDFS) in patie...

3 days ago - Nasdaq

AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials

AstraZeneca (AZN) Reports Positive Data for Enhertu in Early Breast Cancer Trials

3 days ago - GuruFocus

AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain type of breast cancer, according to data announced on Saturday.

3 days ago - Reuters

AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash

AstraZeneca's Enhertu could help some breast cancer patients avoid surgery, according to a study unveiled Saturday at ESMO.

3 days ago - Investor's Business Daily

Amgen And AstraZeneca's TEZSPIRE Approved For Epithelial-Driven Nasal Inflammation

(RTTNews) - Amgen (AMGN) and AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE (tezepelumab-ekko) as an add-on maintenance treatment for inadequately control...

4 days ago - Nasdaq

Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Astrazeneca (AZN) closed at $84.69, marking a +1.03% move from the previous day.

4 days ago - Nasdaq

AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis

AstraZeneca (AZN) Gains FDA Approval for Tezspire in Treating Chronic Rhinosinusitis

4 days ago - GuruFocus

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen's TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years ...

4 days ago - Business Wire

US FDA expands use of Amgen, AstraZeneca's drug for sinus infection

The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic sinus infection, the drugmakers said on Friday.

4 days ago - Reuters

AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects

AstraZeneca (AZN) Rises on U.K.-U.S. Drug Pricing Deal Prospects

4 days ago - GuruFocus

Astra, GSK up after report on U.K. – U.S. drug pricing deal

AstraZeneca (AZN) stock and GSK (GSK) stock gain as the U.K. and U.S. are reportedly clining in on a major drug pricing deal. Read more here.

4 days ago - Seeking Alpha